Page 77 - Read Online

Page 24 of 25 Torres et al. J Cancer Metastasis Treat 2018;4:4 I http://dx.doi.org/10.20517/2394-4722.2017.49

212. Wallecha A, Singh R, Malinina I. Listeria monocytogenes (Lm)-LLO Immunotherapies reduce the immunosuppressive activity of
myeloid-derived suppressor cells and regulatory T cells in the tumor microenvironment. J Immunother 2013;36:468-76.
213. Pan Z, Ikonomidis G, Pardoll D, Paterson Y. Regression of established tumors in mice mediated by the oral administration of a
recombinant Listeria monocytogenes vaccine. Cancer Res 1995;55:4776-9.
214. Wallecha A, Carroll KD, Maciag PC, Rivera S, Shahabi V, Paterson Y. Multiple effector mechanisms induced by recombinant Listeria
monocytogenes anticancer immunotherapeutics. Adv Appl Microbiol 2009;66:1-27.
215. Birmingham CL, Canadien V, Kaniuk NA, Steinberg BE, Higgins DE, Brumell JH. Listeriolysin O allows Listeria monocytogenes
replication in macrophage vacuoles. Nature 2008;451:350-4.
216. Schnupf P, Zhou J, Varshavsky A, Portnoy DA. Listeriolysin O secreted by Listeria monocytogenes into the host cell cytosol is degraded
by the N-end rule pathway. Infect Immun 2007;75:5135-47.
217. Eitel J, Suttorp N, Opitz B. Innate immune recognition and inflammasome activation in Listeria monocytogenes infection. Front
Microbiol 2011;1:149.
218. Weiskirch L, Paterson Y. Listeria monocytogenes: a potent vaccine vector for neoplastic and infectious disease. Immunol Rev
1997;158:159-69.
219. Ikonomidis G, Paterson Y, Kos FJ, Portnoy DA. Delivery of a viral antigen to the class I processing and presentation pathway by
Listeria monocytogenes. J Exp Med 1994;180:2209-18.
220. Mata M, Yao ZJ, Zubair A, Syres K, Paterson Y. Evaluation of a recombinant Listeria monocytogenes expressing an HIV protein that
protects mice against viral challenge. Vaccine 2001;19:1435-45.
221. Singh R, Wallecha A. Cancer immunotherapy using recombinant Listeria monocytogenes: transition from bench to clinic. Hum Vaccin
2011;7:497-505.
222. Tilney LG, Portnoy DA. Actin filaments and the growth, movement, and spread of the intracellular bacterial parasite, Listeria
monocytogenes. J Cell Biol 1989;109:1597-608.
223. Theisen E, Sauer JD. Listeria monocytogenesand the inflammasome: from cytosolic bacteriolysis to tumorimmunotherapy. Curr Top
Microbiol Immunol 2016;397:133-60.
224. Cory L, Chu C. ADXS-HPV: a therapeutic Listeria vaccination targeting cervical cancers expressing the HPV E7 antigen. Hum Vaccin
Immunother 2014;10:3190-5.
225. Shahabi V, Reyes-Reyes M, Wallecha A, Rivera S, Paterson Y, Maciag P. Development of a Listeria monocytogenes based vaccine
against prostate cancer. Cancer Immunol Immunother 2008;57:1301-3.
226. Chen Y, Yang D, Li S, Gao Y, Jiang R, Deng L, Frankel FR, Sun B. Development of a Listeria monocytogenes-based vaccine against
hepatocellular carcinoma. Oncogene 2011;31:2140-52.
227. Keenan B, Saenger Y, Kafrouni M, Leubner A, Lauer P, Maitra A, Rucki AA, Gunderson AJ, Coussens LM, Brockstedt DG, Dubensky
TW Jr, Hassan R, Armstrong TD, Jaffee EM. A Listeria vaccine and depletion of T-regulatory cells activate immunity against early stage
pancreatic intraepithelial neoplasms and prolong survival of mice. Gastroenterology 2014;146:1784-94.
228. Wood L, Paterson Y. Attenuated Listeria monocytogenes: a powerful and versatile vector for the future of tumor immunotherapy. Front
Cell Infect Microbiol 2014;4:51.
229. Brockstedt D, Bahjat K, Giedlin M, Liu W, Leong M, Luckett W, Luckett W, Gao Y, Schnupf P, Kapadia D, Castro G, Lim JY,
Sampson-Johannes A, Herskovits AA, Stassinopoulos A, Bouwer HG, Hearst JE, Portnoy DA, Cook DN, Dubensky TW Jr. Killed
but metabolically active microbes: a new vaccine paradigm for eliciting effector T-cell responses and protective immunity. Nat Med
2005;11:853-60.
230. Li Z, Zhao X, Higgins DE, Frankel FR. Conditional lethality yields a new vaccine strain of Listeria monocytogenes for the induction of
cell-mediated immunity. Infect Immun 2005;73:5065-73.
231. Lauer P, Chow M, Loessner M, Portnoy D, Calendar R. Construction, characterization, and use of two Listeria monocytogenes site-
specific phage integration vectors. J Bacteriol 2002;184:4177-86.
232. Angelakopoulos H, Loock K, Sisul DM, Jensen ER, Miller JF, Hohmann EL. Safety and shedding of an attenuated strain of
Listeria monocytogenes with a deletion of actA/plcB in adult volunteers: a dose escalation study of oral inoculation. Infect Immun
2002;70:3592-3601.
233. Verch T, Pan ZK, Paterson Y. Listeria monocytogenes-based antibiotic resistance gene-free antigen delivery system applicable to other
bacterial vectors and DNA vaccines. Infect Immun 2004;72:6418-25.
234. Sacco JJ, Evans M, Harrington KJ, Man S, Powell N, Shaw RJ, Jones TM. Systemic listeriosis following vaccination with the attenuated
Listeria monocytogenestherapeutic vaccine, ADXS11-001. Hum Vaccin Immunother 2015;12:1085-6.
235. Correction: mesothelin-specific chimeric antigen receptor mRNA-engineered T cells induce antitumor activity in solid malignancies.
Cancer Immunol Res 2015;3:217.
236. Hassan R, Laszik ZG, Lerner M, Raffeld M, Postier R, Brackett D. Mesothelin is overexpressed in pancreaticobiliary adenocarcinomas
but not in normal pancreas and chronic pancreatitis. Am J Clin Pathol 2005;124:838-45.
237. He X, Wang L, Riedel H, Wang K, Yang Y, Dinu CZ, Rojanasakul Y. Mesothelin promotes epithelial-to-mesenchymal transition and
tumorigenicity of human lung cancer and mesothelioma cells. Mol Cancer 2017;16:63.
238. Mkrtichyan M, Chong N, Abu Eid R, Wallecha A, Singh R, Rothman J, Khleif SN. Anti-PD-1 antibody significantly increases
therapeutic efficacy of Listeria monocytogenes (Lm)-LLO immunotherapy. J Immunother Cancer 2013;1:15.
239. Han KJ, Lee NK, Park H, Paik HD. Anticancer and anti-inflammatory activity of probiotic lactococcus lactis NK34. J Microbiol